Travere Therapeutics, Inc.

Travere Therapeutics, Inc. - Enterprise Valueverified

TVTX

Price:

$62.1362

Market Cap:

$5.78B

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the f...[Read more]

Industry

Biotechnology

IPO Date

2012-11-08

Stock Exchange

NASDAQ

Ticker

TVTX

The Enterprise Value as of August 2026 (TTM) for Travere Therapeutics, Inc. (TVTX) is 6.28B

According to Travere Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.28B. This represents a change of 69.24% compared to the average of 3.71B of the last 4 quarters.

Travere Therapeutics, Inc. (TVTX) Historical Enterprise Value (quarterly & annually)

How has TVTX Enterprise Value performed in the past?

The mean historical Enterprise Value of Travere Therapeutics, Inc. over the last ten years is 1.47B. The current 6.28B Enterprise Value has changed 42.54% with respect to the historical average. Over the past ten years (40 quarters), TVTX's Enterprise Value was at its highest in in the June 2026 quarter at 5.81B. The Enterprise Value was at its lowest in in the September 2019 quarter at 634.89M.

Quarterly (TTM)
Annual

Average

1.47B

Median

1.24B

Minimum

703.79M

Maximum

3.64B

Travere Therapeutics, Inc. (TVTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Travere Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 112.22%

Maximum Annual Enterprise Value = 3.64B

Minimum Annual Increase = -39.86%

Minimum Annual Enterprise Value = 703.79M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20253.64B112.22%
20241.72B69.31%
20231.01B-39.86%
20221.69B-13.66%
20211.95B34.26%
20201.45B93.05%
2019753.66M-26.79%
20181.03B35.00%
2017762.56M8.35%
2016703.79M7.70%

Travere Therapeutics, Inc. (TVTX) Average Enterprise Value

How has TVTX Enterprise Value performed in the past?

The current Enterprise Value of Travere Therapeutics, Inc. (TVTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

2.13B

5-year avg

2.00B

10-year avg

1.47B

Travere Therapeutics, Inc. (TVTX) Enterprise Value vs. Peers

How is TVTX’s Enterprise Value compared to its peers?

Travere Therapeutics, Inc.’s Enterprise Value is less than CG Oncology Inc. (6.33B), greater than Tarsus Pharmaceuticals, Inc. (2.59B), greater than Celcuity Inc. (4.60B), greater than Xenon Pharmaceuticals Inc. (5.67B), greater than Centessa Pharmaceuticals plc (6.21B), less than Ascentage Pharma Group International (10.07B), greater than Ultragenyx Pharmaceutical Inc. (2.35B), greater than Legend Biotech Corporation (3.29B), less than Apogee Therapeutics, Inc. (7.86B), greater than Disc Medicine, Inc. (2.93B),

Build a custom stock screener for Travere Therapeutics, Inc. (TVTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Travere Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Travere Therapeutics, Inc. (TVTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Travere Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Travere Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Travere Therapeutics, Inc. (TVTX)?

What is the 3-year average Enterprise Value for Travere Therapeutics, Inc. (TVTX)?

What is the 5-year average Enterprise Value for Travere Therapeutics, Inc. (TVTX)?

How does the current Enterprise Value for Travere Therapeutics, Inc. (TVTX) compare to its historical average?